Silk Road Medical, Inc.

Good day and thank you for standing by. Welcome to the Silk Road Medical third quarter 2023 conference call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising you that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Marisa Beisch with Gil Martin Group, Director of Investor Relations. Marisa, please go ahead.

Great. Thank you for joining today's call. Earlier today, Silk Road Medical released financial results for the three months ended September 30, 2023. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including, without limitation, Those relating to our operating trends and future financial performance, expense management, expectations for hiring and growth in our organization and our business, position training and adoption, market opportunity and penetration, commercial and international expansion, regulatory approvals, reimbursement, competition, and product development are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our latest quarterly report on Form 10-Q filed with the Securities and Exchange Commission. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 8, 2023. Silk Road Medical disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. I will now turn the call over to Jack Lazarson, Chairman of Silk Road Medical's Board of Directors.

Good afternoon, everybody, and thank you for joining us. I am the chairman of Silk Road Medical and have been a director on the board for over 15 years. I wanted to start our call today by welcoming Chas McCann, our new chief executive officer, and offering my excitement for the future of the company. Chas is on the line with us today and alongside Lucas Buchanan, our chief financial officer and chief operating officer. I will turn the line over to Lucas shortly to review our recent performance and drivers of the business. But first, I would like to thank Erica Rogers for her tremendous contributions to the company over the past 11 years. To date, more than 75,000 patients have benefited from the TCAR procedure, which speaks to the incredible impact that the team here at Silk Road has had. Erica has been instrumental in cultivating an enduring mission-focused culture at Silk Road and setting the company apart. We appreciate her leadership and wish her the very best looking forward. Meanwhile, we are thrilled to welcome Chas McCann to the company. Chas has more than 25 years of experience in the medical device industry, with over 20 years in C-suite positions, building and scaling commercial businesses. Most recently, Chas served as President and CEO of Apollo Endosurgery, which was acquired by Boston Scientific in April of this year. At Apollo, Chas created and led a transformational growth strategy for the company's minimally invasive technologies for gastrointestinal and bariatric conditions. Previously, he held commercial officer roles at Tourex Medical and Intersect E&T, as well as leadership positions at Boston Scientific and Johnson & Johnson. We're confident that Chas is the right leader alongside Lucas and the full leadership team to leverage our strong infrastructure, skilled commercial team, and substantial body of clinical evidence to take the company further on the journey to treat patients with carotid artery disease. Under his leadership, Silk Road remains committed to the same mission, vision, and values that have guided us since its founding. We look forward to executing a smooth transition and continue expanding our impact for patients. Our company faces a substantial under-penetrated market opportunity, and we will continue to prioritize the growth and adoption of TCAR in this context. With that, I'll turn the line over to Lucas to review third quarter performance and trends in the business. Thank you.